TGTX 12.55 Tg Therapeutics $TGTX Hit a 52 week high of

New Post Public Reply Private Reply Replies (0) Message Board

Nov 11, 2014 at 1:26 AM

TGTX 12.55 Tg Therapeutics $TGTX Hit a 52 week high of 12.61 Closing the day 11/10/14 at 12.55 +1.28 +11.36% With a day low of 11.26 and a total volume of 693,254.

TGTX Recent Posts: http://investorshangout.com/TG-Therapeutics-Inc-TGTX-64219/

TGTX Tg Therapeutics Recent Headline News

Nasdaq stocks posting largest percentage increases
AP - Mon Nov 10, 5:07PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
OREX: 5.13 (+1.28), PCMI: 8.80 (+1.35), ACHN: 12.85 (+2.74), TGTX: 12.55 (+1.28), AGIO: 81.78 (+9.72), LIOX: 5.54 (+0.80), PLNR: 7.68 (+1.28)

TG Therapeutics misses by $0.19
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 4:12PM CST

TGTX: 12.55 (+1.28)

TG Therapeutics, Inc. Announces Third Quarter 2014 Financial Results and Business Update
GlobeNewswire - Mon Nov 10, 3:20PM CST
TG Therapeutics, Inc. (Nasdaq:TGTX), an innovative clinical-stage biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for cancer and autoimmune diseases, today announced its results for the third quarter ended September 30, 2014 and recent company developments.
TGTX: 12.55 (+1.28)

TG Therapeutics reports November 11
Seeking Alpha - at Seeking Alpha - Fri Nov 07, 3:10PM CST

TGTX: 12.55 (+1.28)

TG Therapeutics, Inc. to Host Conference Call on Third Quarter 2014 Financial Results and Business Update
GlobeNewswire - Fri Nov 07, 3:00PM CST
TG Therapeutics, Inc. (Nasdaq:TGTX), announced today that a conference call will be held on Tuesday, November 11, 2014 at 8:30am ET to discuss results for the third quarter of 2014 and provide a business outlook for the remainder of the year. Michael Weiss, Executive Chairman and Interim Chief Executive Officer, will host the call.
TGTX: 12.55 (+1.28)

TG Therapeutics, Inc. Announces Data Presentations at the Upcoming 56th American Society of Hematology Annual Meeting
GlobeNewswire - Thu Nov 06, 8:45AM CST
Combination of TG-1101, the Company's Novel Glycoenginereed Anti-CD20 Monoclonal Antibody and TGR-1202, the Company's Once Daily PI3K Delta Inhibitor to be Highlighted in Oral Presentation
TGTX: 12.55 (+1.28)

Strong On High Relative Volume: TG Therapeutics (TGTX)
at The Street - Mon Oct 27, 9:00AM CDT
Trade-Ideas LLC identified TG Therapeutics (TGTX) as a strong on high relative volume candidate
TGTX: 12.55 (+1.28)

Ligand Earns Milestone Payment on EU Approval of Noxafil - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Oct 02, 12:00PM CDT
Ligand Pharmaceuticals Incorporated (LGND) earned a $550,000 milestone payment from partner Merck (MRK) on the EU approval of Noxafil (posaconazole) for infusion.
MRK: 58.81 (-0.53), TGTX: 12.55 (+1.28), LGND: 55.68 (+1.74), AMGN: 163.09 (+2.84)

TG Therapeutics reports exercise of its option to license the global rights to TGR-1202
M2 - Wed Sep 24, 6:17AM CDT
Biopharmaceutical company TG Therapeutics (NasdaqCM :TGTX) said on Tuesday that it has exercised its option to license the global rights to TGR-1202 from Rhizen Pharmaceuticals.
TGTX: 12.55 (+1.28)

Rhizen Pharmaceuticals Announces Out-licensing Agreement for TGR-1202, a Novel Next Generation PI3K-delta Inhibitor
GlobeNewswire - Tue Sep 23, 9:39AM CDT
Rhizen Pharmaceuticals S.A. today announced an out-licensing agreement for TGR-1202, a novel next generation PI3K-delta inhibitor. TG Therapeutics exercised its option for early conversion to a licensing agreement from a 50:50 joint venture partnership.
TGTX: 12.55 (+1.28)

TG Therapeutics Announces Exercise of License Option for Its Novel, Next Generation PI3K-Delta Inhibitor, TGR-1202
GlobeNewswire - Tue Sep 23, 6:30AM CDT
TG Therapeutics, Inc. (Nasdaq:TGTX) today announced that it has exercised its option to license the global rights to TGR-1202, the Company's novel, next generation PI3K-delta inhibitor from Rhizen Pharmaceuticals, S A ("Rhizen"

. The Company and Rhizen have to date been jointly developing TGR-1202 in a 50:50 joint venture. Given the successful development of TGR-1202, TG Therapeutics elected an early exercise of the Company's license option.
TGTX: 12.55 (+1.28)

TG Therapeutics (TGTX) in Focus: Stock Gains 16.1% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Sep 18, 8:46AM CDT
TG Therapeutics (TGTX) was a big mover last session, with shares rising over 16% on the day.
ICUI: 71.81 (+0.65), ABAX: 52.94 (+1.31), TGTX: 12.55 (+1.28), EGRX: 13.50 (+1.02)

TG Therapeutics Announces Special Protocol Assessment (SPA) Agreement With the FDA for Its First Phase 3 Clinical Trial of TG-1101 (ublituximab) in Combination With Imbruvica(R) (ibrutinib) for Patients With Previously Treated Chronic Lymphocytic Leukemia
GlobeNewswire - Mon Sep 15, 6:08AM CDT
Overall Response Rate (ORR) to be the Primary Endpoint to Support Accelerated Approval with Progression-Free Survival (PFS) to Support Full Approval
TGTX: 12.55 (+1.28)

UPDATE -- TG Therapeutics, Inc. to Present at the 16th Annual Rodman & Renshaw Global Investment Conference
GlobeNewswire - Mon Sep 08, 3:28PM CDT
In a release issued earlier today by TG Therapeutics, Inc. (Nasdaq:TGTX), please note the company's scheduled presentation time has changed to 1:15 PM ET, from 1:40 PM ET previously. The updated release follows:
TGTX: 12.55 (+1.28)

TG Therapeutics, Inc. to Present at the 16th Annual Rodman & Renshaw Global Investment Conference
GlobeNewswire - Mon Sep 08, 9:12AM CDT
TG Therapeutics, Inc. (Nasdaq:TGTX), an innovative, clinical-stage biopharmaceutical company today announced that Michael Weiss, the Company's Interim Chief Executive Officer, will be presenting at the 16 Annual Rodman & Renshaw Global Investment Conference being held at the New York Palace Hotel. Mr. Weiss' presentation is scheduled to take place on Tuesday, September 9, 2014 at 1:40 PM ET. A live webcast of this presentation will be available on the Events page, located within the Investors & Media section of the Company's website at www.tgtherapeutics.com.
TGTX: 12.55 (+1.28)

TG Therapeutics (TGTX) Worth Watching: Stock Up 9.1% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Sep 04, 7:44AM CDT
TG Therapeutics (TGTX) was a big mover last session, as the company saw its shares rise over 9% on the day.
ICUI: 71.81 (+0.65), ABAX: 52.94 (+1.31), TGTX: 12.55 (+1.28), ATRC: 17.69 (+0.83)

Ligand Up on Multi-Program Captisol Deal with Avion Pharma - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Aug 18, 4:10PM CDT
Ligand Pharmaceuticals Incorporated (LGND) entered into a deal with Avion Pharmaceuticals, LLC, under which four Captisol-enabled programs will be developed and commercialized.
TGTX: 12.55 (+1.28), LGND: 55.68 (+1.74), AMGN: 163.09 (+2.84)

TG Therapeutics Inc. (TGTX) Stock Research Links

TGTX Board Company Profile Buy Rating Time & Sales News Filings Financials

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Revamp Preschool Questions for Richer Conversations

Preschoolers, those tiny agents of chaos, come home with stories that you'd need a magnifying glass to find. Ask 'em "How was school?" and you're met with blank stares or a one-liner. Tami Nix of Archway Academy has been at this game for over 40 years, and she's got a trick or six up her sleeve. Ditch the Generic: Get Specific Yep, those generic questions are about as...

Govee's Retro Holiday Lights: A Festive Nostalgia Trip

Ah, the holidays—they're creeping up like a kid sneaking downstairs for a peek at their gifts. But it's not the gifts under the tree that brighten a room, it's those lights draping the tree itself. Enter Govee, bringing us back to that vintage glow we all remember from our childhoods. They've teamed up with Brady Tolbert, a design whiz who can make a living room look...

Electra's Ultra Short Aircraft Revolutionizes Air Travel

From Tarmacs to Heliports: A New Era in Air Travel The aviation world doesn’t often see a sea change, but when a fixed-wing flyer touches down at a heliport, it grabs your attention. Electra’s recent leap into Manhattan’s Downtown Skyport highlights a promising shift in regional air mobility, doing away with the age-old reliance on long runways. It’s a shift that...

Pacsun Finds Gear: 177% Sales Surge at F1 Austin!

New Heights in Trackside Fashion Well, it looks like Pacsun's got a knack for making the Austin F1 scene as thrilling as the race itself, weaving fashion into the high-speed atmosphere. This year's Formula 1 United States Grand Prix in Austin brought a whopping 19% sales swell in 2026, marking a total sales increase of 177% since their initial 2023 Austin pop-up. Talk...

Everyday Innovation Shines at Canton Fair 2026

Subtle Brilliance in Daily Design You could be swimming in breakthrough tech and miss the real gems — like those sly innovators at this year's Canton Fair. They're overhauling the basics, making ordinary stuff extraordinary with a flick of the wrist. It’s not always the big flashy gadgets that steal the show; sometimes it’s the stealthy little tweaks. Knife...

STARMUS VIII: Bridging Science, Music, and Society

A Constellation of Luminaries at STARMUS You think you've seen it all on this spinning rock, and then something like STARMUS VIII comes around to shake up your perspective. From the Canary Islands, the world just got a little more interesting. We're talking a line-up that could humble the stars themselves—scientific pioneers, musical legends, and cultural icons all...

Bank of America Faces Class-Action Suit in Court

Mixed Bag for Bank of America Investors If you thought you could just park your cash in big banks and slumber through the financial year, think again. Bank of America (NYSE: BAC) has found itself in hot water with a securities fraud class-action suit looming over what some are calling a pretty nasty oversight in compliance. A 4.76% stock drop was a bitter sip for those...

Sands China's Latest Move: A Bond Offering Twist

Breaking Down Sands China's Bond Maneuver Today, we found out that Sands China is teeing up a fresh round of senior unsecured notes. Now, if that doesn't get your ticker flickin', maybe you're too used to market snoozefests. The folks at the helm of Sands China, a subsidiary under the mighty Las Vegas Sands Corp. (NYSE: LVS), are rolling out these USD-denominated notes...

Landis+Gyr's Big Contract Victory: A Game Changer?

Diving into Landis+Gyr's Major Utility Win When news hits about a deal secured by Landis+Gyr Group AG, it rings a few bells across the utility landscape. These folks have brewed up a storm with a fresh contract that slots into their rapidly expanding portfolio of grid-savvy products. So, what’s the fuss about this latest agreement? A Groundbreaking Contract Now, this...

3TREES Debuts Green Coatings to East African Market

3TREES Rocks East Africa's Construction Scene Nairobi's got a spark this week, and it's radiating straight from 3TREES' corner at the Big 5 Construct Kenya. With the Sarit Expo Centre buzzing from October 21, 2026, this Chinese company didn't just show up—they made one hell of an entrance. Presenting eco-friendly coating solutions, they pushed the 'Create Healthy Life'...